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ABSTRACT
There is increasing concern globally about the enormity 
of the threats posed by antimicrobial resistance (AMR) 
to human, animal, plant and environmental health. A 
proliferation of international, national and institutional 
reports on the problems posed by AMR and the need 
for antibiotic stewardship have galvanised attention 
on the global stage. However, the AMR community 
increasingly laments a lack of action, often identified as 
an ‘implementation gap’. At a policy level, the design of 
internationally salient solutions that are able to address 
AMR’s interconnected biological and social (historical, 
political, economic and cultural) dimensions is not 
straightforward. This multidisciplinary paper responds by 
asking two basic questions: (A) Is a universal approach to 
AMR policy and antibiotic stewardship possible? (B) If yes, 
what hallmarks characterise ‘good’ antibiotic policy? Our 
multistage analysis revealed four central challenges facing 
current international antibiotic policy: metrics, prioritisation, 
implementation and inequality. In response to this 
diagnosis, we propose three hallmarks that can support 
robust international antibiotic policy. Emerging hallmarks 
for good antibiotic policies are: Structural, Equitable and 
Tracked. We describe these hallmarks and propose their 
consideration should aid the design and evaluation of 
international antibiotic policies with maximal benefit at 
both local and international scales.
INTRODUCTION: ANTIMICROBIAL RESISTANCE AS 
A BIOSOCIAL PROBLEM
Since their introduction in the 1930s, anti-
biotics have acquired infrastructural impor-
tance in global health and food produc-
tion.1 However, antibiotic reliance comes 
with a trade- off: using antibiotics accelerates 
the emergence of antimicrobial resistance 
(AMR), which diminishes their future effec-
tiveness. This makes effective antibiotics a 
precious ‘global common- pool resource’,2–6 
which can benefit humanity but will provide 
diminishing benefits if we fail to coordi-
nate plans for preservation (a tragedy of the 
commons).
Over the past decade, rising concern 
about AMR has highlighted the need for 
collective action to protect our antibiotic 
‘commons’.2 7–12 Governmental and non- 
governmental organisations have devoted 
substantial resources to tackling AMR and 
preserving antibiotic effectiveness on national 
and international stages.13 Increasing atten-
tion and funding have been accompanied 
by a proliferation of expert reports and 
policy proposals.14 While these AMR- focused 
initiatives have succeeded in achieving a 
clear international consensus on the need 
for action, many lament a lack of action in 
practice, dubbed an ‘implementation gap’. 
Substantial uncertainties also remain about 
Summary box
 ► The global crisis of antimicrobial resistance has led 
to a proliferation of expert reports and national and 
international antibiotic action plans.
 ► Implementing international antibiotic policy that is 
meaningful in different social, cultural and economic 
contexts continues to prove challenging.
 ► Our multidisciplinary analysis has identified four 
critical challenges of metrics, prioritisation, imple-
mentation and inequality for international antibiotic 
policy- making.
 ► We propose a corresponding SET of basic hall-
marks of good antibiotic policy, which we define as 
Structural, Equitable and Tracked.
 ► Our SET of hallmarks can orientate disciplinary de-
bates and provide a framework for developing robust 
international interventions.
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the effects of different policy interventions, how interna-
tional policies could be enforced globally, and who will 
pay in the long term. The main difficulty with managing 
the antibiotic commons seems to lie in jointly addressing 
the complex biological and social (understood here to 
be historical, political, economic and cultural) dimen-
sions of AMR. Policy formation for the latter dimension 
is particularly challenging because it entails addressing 
different metrics, meanings and challenges in different 
settings.
We propose a new wide- angle approach to AMR- 
focused antibiotic regulation. Two basic questions guide 
our reflective process: (A) Is a universal approach to 
AMR policy and antibiotic stewardship possible? (B) If 
yes, what hallmarks characterise ‘good’ antibiotic policy?
To answer these questions, we have developed an inno-
vative heuristic evaluation framework, which accounts 
both for AMR’s biological and social facets. Our approach 
was informed by the numerous national and interna-
tional reports proposing various principles for antibiotic 
policy- making2 10 11 15–17 and the historical success of the 
3Rs (Reduction, Refinement and Replacement) that 
restructured laboratory animal testing protocols. Devel-
oped as principles of ‘good animal experimentation’ in 
1959, the 3Rs were concrete and aspirational enough to 
trigger a progressive evolution of protocols and dialogue 
in a contested policy arena.18(So et al have proposed 
three Rs for antimicrobial development).19
Applying this approach to AMR and antibiotic policy, 
our collaborative multidisciplinary analysis employed a 
three- stage evidence gathering, evaluation and consul-
tation process (box 1), which consisted of: (1) asking 
selected medical humanities and sciences researchers 
whether they believe antibiotic policies could feasibly 
be guided by a universal set of guiding principles, and 
what they consider those guiding principles could be; 
(2) identifying possible hallmarks of good policy with a 
broad group of stakeholders from academia, medicine, 
animal/plant production, policy and funding bodies at 
an international workshop and (3) refining identified 
hallmarks in light of multidisciplinary feedback.
We believe that the resulting heuristic compass based 
first on the identification of central challenges of anti-
biotic policy- making (metrics, prioritisation, implemen-
tation, inequality) and second on the formulation of a 
corresponding Structural, Equitable and Tracked (SET) 
of hallmarks of good antibiotic policy, which we define 
as SET can orientate disciplinary debates and provide a 
framework for robust international interventions.10 20 21
THE FOUR CENTRAL CHALLENGES OF ANTIBIOTIC REGULATION
Metrics
Despite long- standing regulation attempts, there remains 
substantial uncertainty about basic metrics surrounding 
antibiotic usage and AMR as well as about how to corre-
late measurements in a way that can inform meaningful 
policy formulation at the national and international 
levels.22
How to define resistance?
Since the first warnings about ‘drug fastness’ in micro-
organisms in 1907,23 24 there has been no clear transdis-
ciplinary or international consensus on how to define 
AMR. The constantly evolving nature of AMR, the 
Box 1 Three stage evidence gathering, evaluation and 
consultation process
Stage 1:
Following a 2018 Social Science and antimicrobial resistance 
(AMR) Research Symposium at the British Academy in London,162 a 
correspondence group of fourteen experts from the humanities, social, 
environmental and medical sciences reflected on whether there could 
be universal principles of international antibiotic policy making and 
hallmarks of ‘good’ policy.
Stage 2:
Identified policy challenges and core hallmarks of successful 
intervention informed a preliminary paper, which was circulated 
among correspondents and attendees of a multidisciplinary 2- day 
workshop in London in March 2019.
During presentations, small group breakout sessions, and group 
discussions, participants reflected on the preliminary paper’s four 
identified problem areas for antibiotic regulation: (A) metrics (defining 
and measuring AMR, antibiotic usage and performance indicators for 
interventions); (B) prioritisation (prioritising specific forms of antibiotic 
use over others); (C) implementation (developing and implementing 
interventions that are meaningful in high- income, medium- income 
and low- income settings); (D) inequality (formulating interventions 
that take into account global disparities of wealth, infectious disease 
and AMR burdens and access to antibiotics as well as effective health, 
water, sanitation and hygiene systems).
There was agreement on these interlinked problems but the 
four provisional hallmarks proved more contentious: (1) antibiotic 
policymaking should take into account antibiotics’ infrastructural 
relevance in medicine and food production; (2) should increase the 
microbial resilience of health and food systems to diminish the need 
for antibiotics; (3) be responsive to evolving knowledge regarding AMR 
and (4) relational in its acknowledgement of differing local challenges 
and capacities.
Participants agreed that there was no single solution to AMR but 
felt that hallmarks needed to be integrated and go beyond preserving 
the status quo. Key to more effective policymaking has to be an 
acknowledgement of antibiotics’ primary utility for global health and 
food production, which consists in their ability to reduce mortality 
and morbidity resulting from treatable infections. To preserve this 
utility, the overriding aim of any antibiotic policy must therefore be 
(1) to maximise and maintain access to effective treatments for 
infections, which includes the development of new treatments—while 
(2) reducing the need for antibiotic use by preventing infections, 
reducing antibiotic dependencies in healthcare and food systems, 
and minimising the environmental load of antibiotics and resistant 
bacteria.
Stage 3:
A refined version of new Structural, Equitable, Tracked Hallmarks was 
circulated among correspondents and participants, who were invited 
to be coauthors on the paper.
M
edicine. Protected by copyright.
 o
n
 Septem
ber 25, 2020 at Liverpool School of Tropical
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from 
Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091 3
BMJ Global Health
introduction of new drugs and the different availability 
and use of antibiotics means that terms like drug sensi-
tive, intermediate resistant or resistant, mean different 
things in different regional contexts. There is also no 
transdisciplinary consensus on whether to define AMR 
according to predefined clinical breakpoints, minimum 
inhibitory concentrations, epidemiological cut- offs, phar-
macokinectic/pharmacodynamic models, the presence 
or absence of resistance- conferring genetic elements or 
clinical impact on patients or animals. Disagreement over 
this latter point is highlighted by the common absence 
of drug- resistant infection as an official cause of death. 
Historically, the lack of consensus over AMR has led to 
differing microbiological and public health definitions 
of AMR with the former measuring incremental changes 
of microbial susceptibility and the latter measuring 
instances of treatment failure at predefined dosages.25–27
Whose methods count?
Internationally, the establishment of WHONET (est. 
1989) and WHO’s Global Antimicrobial Resistance 
Surveillance System (GLASS, est. 2015) marked impor-
tant efforts to standardise AMR reporting in humans 
and make data comparable.28 29 However, coordina-
tion problems remain: testing protocols by influential 
bodies like the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) and the US- based Clin-
ical Laboratory Standards Institute (CLSI) occasionally 
diverge. Resulting international monitoring differences 
are exacerbated by issues of access (see problem area 
Inequality).30 EUCAST guidelines and updates are avail-
able free of charge. By contrast, CLSI guidelines and 
updates are often pay for use, which makes it difficult for 
resource poor laboratories to keep protocols up to date 
and feedback local AMR data into international data-
bases.31 In low and middle income countries (LMICs), 
surveillance is often further complicated by lack of access 
to laboratory equipment, service contracts and paywalled 
literature.32 Ensuing disparities in global AMR reporting 
mean that international reports disproportionately reflect 
data from resource- rich settings and a limited number of 
well- studied low- income sentinel sites with international 
healthcare infrastructure investment.33 Resulting inter-
national stewardship and policy guidelines may, however, 
be of limited use in understudied resource- poor settings 
with different AMR ecologies and no access to key anti-
biotics.
What is relevant antibiotic use data for AMR?
Capturing relevant data on antibiotic use to inform 
AMR efforts has its own challenges. Starting in the 
1990s, various high income countries (HICs) began to 
compile antibiotic usage data.34–37 However, data collec-
tion methods continue to vary. In the case of antibiotic 
usage in animals, the World Organisation of Animal 
Health (OIE) has begun to collect data on antibiotic 
sales intended to be used in animals and usage data 
since 2015. However, despite ongoing progress, data gaps 
remain with almost 25% of 182 OIE Member Countries 
not reporting quantitative and most reporting antibiotic 
sales and imports data but no data on use for the fourth 
OIE round of data collection.38 Reporting differences 
are also common among HICs. The EU developed a 
standardised metric to correlate antibiotic sales with the 
volume of animal production (mg/population correc-
tion unit) from 2010 onwards.39 Individual EU countries 
like Britain and Denmark publish not just sales but farm 
usage and prescription data for certain livestock catego-
ries.40 41 By contrast, the US Food and Drug Administra-
tion (FDA) publishes sales data only in broad categories 
of drug class by species but no usage data, which compli-
cates AMR risk assessment.42
Correlating usage and AMR data is even more chal-
lenging. In its 2018–2019 report, the English Surveillance 
Programme for Antimicrobial Utilisation and Resistance 
(ESPAUR) showed a significant reduction in antibiotic 
prescriptions but an increase in antimicrobial- resistant 
infections for the seven priority bacterial pathogens 
reported.43 In 2017 and 2019, longitudinal studies of 
bloodstream infections in Malawi showed a long- term 
reduction of overall infections but a rise of antibiotic 
resistance in remaining infections.33 44 To be useful, 
aggregated metrics of antibiotic usage (including class of 
antibiotic) across infection types need to be contextual-
ised with outcome and population health metrics, such as 
infection, resistance and morbidity/mortality rates.45–47
Understanding what the implications of specific forms 
of antibiotic usage (eg, prophylaxis, therapy, growth 
promotion) in different environments are for AMR and 
health outcomes is similarly crucial for policy formula-
tion. Rising numbers of point prevalence studies and 
whole- genome sequencing are enhancing our knowl-
edge of drivers and variations of AMR over time and in 
different areas across the world.48–51 However, our wider 
understanding of the evolutionary factors underlying 
AMR levels is still fragmentary as is our understanding of 
which stewardship interventions might make how much 
of a difference: in some cases like targeted 1950s anti-
biotic prescription bans at St Bartholomew’s Hospital 
in London52 or Denmark’s 1990s ban of lower- dosed 
avoparcin and tylosin animal growth promoters, reducing 
selection pressure by a specific type of drug usage led to a 
marked reduction, but not a complete disappearance, of 
correlating AMR.53 54 In other cases, antibiotic reductions 
may take years to manifest in terms of reduced AMR—as 
highlighted by the UK’s 2019 ESPAUR report and expe-
riences in Scandinavian countries.43 53 55 Finally, some 
usage reductions may come too late to shift the evolu-
tionary balance back in favour of microbial sensitivity as 
occurred with China banning the use of colistin growth 
promoters in 201656 following a report of the transferable 
mobilisable colistin resistance MCR-1 gene.57 Subsequent 
reports, however, showed that the gene was detectable in 
strain collections from more than 30 countries and was 
already circulating in Escherichia coli in China in the mid 
1980s.58 The lack of uniformly comparable data makes 
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it more difficult to evaluate trade- offs in various policy 
options.
How to develop meaningful key performance indicators?
While uncertainty remains about the degree to which 
interventions will be effective, reducing the overall 
amount of antibiotics used in health and animal and plant 
production systems is a key component of most AMR 
action plans.11 13 59 Over the past two decades, interna-
tional bodies have attempted to decide which antibiotics 
to protect from overuse. Since 2004, WHO, OIE and the 
Food and Agriculture Organization (FAO) have begun 
using the categories of critically important antimicrobials 
(CIAs), highly important antimicrobials and important 
antimicrobials—although differences in the categorisa-
tion of the same drugs for veterinary and medical usages 
can remain.60 61 In 2019, the WHO’s Essential Medicines 
List added the AWaRe categorisation, to meet a need 
to recognise those medicines that should be Accessed as 
first- line narrow- spectrum treatment for particular condi-
tions, and those with higher risks of becoming resistant 
that should be used Watchfully and those that should be 
Reserved for last- line treatment.62 This framework can 
be used as an index—the ratio of Access to Watch and 
Reserve medicines—to compare prescribing practices in 
different contexts, which goes some way to balancing the 
different challenges of improving access and restricting 
excess when setting targets.63 However, measurement of 
antibiotic usage remains a challenge. Although WHO and 
OIE have standardised methodologies to collect country- 
level antimicrobial usage in humans and animals for 
global reporting and consulting companies like IQVIA 
gather and sell additional proprietary data,64 65 more 
granular level detail about antibiotic usage on farms and 
in particular clinical and residential settings is required 
for targeted reduction strategies.66 67
Alongside improved usage data, deciding which 
microbes, resistance genes and AMR reservoirs to 
monitor in medical, animal and plant production, and 
environmental settings is similarly important for the 
formulation of meaningful policy interventions. For 
humans, WHO published a list of priority pathogens to 
monitor and target with antibiotic development efforts in 
2017.68 For animals, the OIE Member Countries agreed 
on harmonised lists for both terrestrial and aquatic 
animals.69 70 However, it remains difficult to prioritise 
which sentinel organisms to survey and where potentially 
important AMR reservoirs are located due to different 
health threats in HICs, MICs and LICs, lacking clinical 
surveillance infrastructure in many LMICs and of envi-
ronmental surveillance in the most countries, regionally 
skewed reporting that often centres on urban clinical 
settings, and limited diagnostic capabilities for non- classic 
pathogens.71 72 Furthermore, particular microbes such as 
Staphylococcus aureus and E. coli may or may not be causing 
disease, and therefore, their measurement without corre-
sponding disease burden data might be misleading.
Discussed in more detail below (see Tracked), one 
recently proposed solution for human health might be 
to integrate AMR and infection burden measurements 
by tracking two priority organisms in bloodstream infec-
tions as part of United Nations (UN) Sustainable Devel-
opment Goal (SDG) 3.d.1. This new AMR- specific SDG 
could help build laboratory capacity in resource- poor 
settings and spur the development of further integrated 
AMR- specific metrics. Another approach might be to 
strengthen point prevalence studies for specific sentinel 
organisms in LMIC settings.73 (Consultations on sentinel 
organisms and sentinel sites are ongoing by GLASS and 
the point prevalence survey).
The described temporal and contextual challenges of 
defining resistance, measuring antibiotic usage in rela-
tion to AMR and concerning which microbes to focus on 
also raise important questions when it comes to defining 
benchmarks or key performance indicators (KPIs) for 
policy initiatives: how far should antibiotic sensitivity 
be restored or preserved for a measure to be consid-
ered successful? Should the performance of a policy be 
linked to its reduction of antibiotic usage or should the 
KPI be demonstrated impact on human health? Should 
success be defined as the stabilisation or decline of AMR 
in specific culturable pathogens? Given the mobility of 
resistance genes and the One Health dimensions, should 
a metric of success be the abundance or prevalence of 
a particular resistance gene in the wider environment, 
determined through quantitative PCR methods74? How 
much time should policies have to achieve their goals?
Prioritisation
Overemphasis on surveillance data itself can serve to 
obscure different regional capabilities, underlying polit-
ical interests and competing needs in animal and human 
medicine.75 In addition to defining meaningful metrics, a 
significant challenge facing international antibiotic regu-
lation is which form of antibiotic use to prioritise in the 
face of time- limited microbial sensitivity to most drugs 
and heterogeneous epidemiological, social, economic 
and material contexts. The challenge of prioritisation 
comprises spatial and temporal components.
Spatial: since the 1940s, regulators have tried to protect 
important antibiotics by restricting their use,76 but this 
path- dependent prioritisation has been enacted differ-
ently across varying local, regional and national settings. 
Antibiotics’ infrastructural importance in global health-
care and food production means that a large number of 
sectors with different needs depend on routine antibi-
otic access.1 In the case of Europe and North America, 
historians have shown that distinct national antibiotic 
usage patterns have become socially entrenched over 
decades.77–81 To this day, antibiotic usage patterns vary 
across Europe and North America despite both regions' 
close economic, political and cultural ties.82 83 Differ-
ences of usage are even more substantial between HICs 
and LMICs with patients in the latter countries often 
depending to a much stronger degree on the efficacy 
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of a limited number of locally available, affordable and 
easily administrable drugs—particularly in areas where 
there is no access to professional healthcare facilities.84–86 
If different countries, sectors and even local healthcare 
facilities87 use different antibiotics for a variety of biolog-
ical and social reasons, whose form of antibiotic use 
should receive priority?
The same problems of spatial prioritisation hold true 
in animal and plant production.34 88 One example of 
spatialised inequality of access are the polymyxin antibi-
otics (eg, colistin, discovered in 1949). After using the 
drugs to treat gram- negative infections in humans, HICs 
greatly reduced use of polymyxins in favour of less toxic 
carbapenems from 1980 onwards.89 Although limited use 
of ‘old’ colistin continued in HICs, their low cost and 
lacking HIC demand for human medicine led to aggres-
sive pharmaceutical marketing and large- scale uptake 
for growth promotion and disease prevention in the 
industrialising animal production of LMICs like China 
and Brazil.88 When rising carbapenem resistance led to a 
resurgence of polymyxin use in human medicine around 
2005, competing animal production and medical priori-
ties meant that global regulators did not raise polymyxins’ 
status to that of CIAs. It was only after the discovery of the 
mcr-1 gene on transferable plasmids in bacterial isolates 
from Chinese pigs that polymyxins were recategorised as 
highest priority CIAs in 2016, received specific restriction 
recommendations from OIE, and were banned from use 
as growth promoters in China and Brazil.57 60 75
Temporal: another challenge of prioritisation regards 
the inevitable temporal conflict between acute health-
care needs and the future- focused dimensions of anti-
biotic stewardship.90 There is a well- evidenced ethical 
dilemma between preserving drugs’ future efficacy and 
using antibiotics to safe- guard vulnerable populations in 
the present. This is highlighted by studies on the rise of 
multidrug- resistant pathogens in itinerant and immuno-
compromised HIC and MIC populations91–94 or of AMR 
proliferation as a result of high levels of antibiotic use 
in prolonged crisis situations like the 2009 H1N1 influ-
enza or the current COVID-19 pandemic.95–98 Similar 
dilemmas have also become apparent in campaigns of 
antimicrobial mass drug administration to prevent child 
stunting,99 100 against onchocerciasis, lymphatic filariasis 
or malaria,101 in the mass administration of azithromycin 
against drivers of childhood mortality in Tanzania, Niger 
and Malawi,102 103 and to prevent scabies and impetigo on 
the Solomon Islands.104
Answers to this temporal dilemma vary and reflect 
the perceived severity of need, cultural preferences for 
specific forms of use, and economic considerations. In 
some cases, the potential longer- term risk to public health 
of antibiotic resistance has been favoured over immediate 
clinical needs.105 However, in the main, present needs 
have overridden future- focused stewardship concerns. 
While there is no reason not to use antibiotics to save 
and improve lives, they have often been used as a ‘quick 
fix’106 to symptomatically control rather than eliminate 
underlying drivers of infection in human, animal health 
and plant production systems. The tendency to see anti-
biotics as ‘quick fixes’ has helped drive AMR and often 
distracted from investment in more sustainable forms of 
infection prevention like effective and affordable health, 
Water, Sanitation and Hygiene (WASH), and Infection 
Prevention Control (IPC) systems (see also Inequality 
below).85 Over- reliance on antibiotics has also been exac-
erbated by industry marketing of, in part, inappropriate 
antibiotic usage and targeted campaigning to under-
mine usage restrictions in high- income and low- income 
settings.34 77 107
Implementation
A third fundamental challenge for antibiotic policy- 
making concerns the formulation of binding interna-
tional agreements that can still be implemented flexibly 
in different settings.17 108 Recent international agree-
ments like the 2016 UN Paris Agreement on climate 
change remain based on the classic so- called Westphalian 
model of sovereign nation- states agreeing on a set of 
measures, which are then independently enacted within 
their borders without control by other actors.7 12 109 110 
There are a number of challenges with this model: global 
trade flows are not easily regulated by nation- level poli-
cies; with few exceptions like the International Health 
Regulations on pandemics, international organisations 
like the WHO cannot enforce health agreements nego-
tiated under their umbrella; the ability of governments 
to implement policies varies.8 20 110 111 Described imple-
mentation problems are exacerbated by the widespread 
absence of basic data and robust metrics (see above) to 
inform international policymaking. For example, while it 
may seem straightforward to define and evaluate policy 
success as reductions of drug usage in HICs, these metrics 
will likely fail in settings without reliable consumption/
usage data and where informal grey market and unreg-
ulated over- the- counter sales account for a large part of 
the antibiotic supply.82 112 113
Using an integrated political, economic, sociolog-
ical, technological, ecological, legislative and industry 
framework, reviews of national action plans proposed 
after the 2015 Global Action Plan on Antimicrobial 
Resistance have warned of continuing gaps in applying 
international concepts of stewardship at the national 
level.114 115 Focusing only on international and not on 
actual local policy alignment can foster the creation 
of ‘paper tiger’ initiatives, which are not enforced—as 
in the case of enacted but not enforced bans of over- 
the- counter antibiotic sales116—or obscure or relabel 
existing practices rather than reform underlying antibi-
otic infrastructures.13 117 118 Follow- up reports by WHO, 
UN and World Bank have proposed solutions including 
international investment in local IPC, antibiotic quality 
assurance and access schemes, AMR surveillance, vacci-
nation, local stewardship champions and contextualised 
policy- making.10 20 21 111 In the case of animal production, 
experts have proposed using AMR monitoring in sentinel 
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pathogens and technical support from HICs as tools to 
incentivise global reductions of antibiotic usage.119 Prom-
ising access to lucrative markets and using transnational 
integration to promote precautionary antibiotic policies 
is an additional tool that was used by the UK in the 1970s, 
Sweden in the 1990s, and is now being considered by the 
EU to reduce antibiotic growth promoter and prophy-
lactic antibiotic use in non- European countries.34 120
However, so far, enactment of proposed measures 
has been fragmentary13 and it remains unclear how 
numerous national and international calls to action with 
complex interlayered principles of action can be trans-
lated into effective change in settings where antibiotic 
access is lacking and AMR is secondary (at best) to other 
health concerns. Looking beyond top- down nationstate 
alignment, by reemphasising municipal and community- 
based health initiatives as well as creating new metrics for 
antibiotic access before prioritising stewardship may be a 
solution. Recent social sciences research suggests the effi-
cacy of adaptive value- driven bottom- up reforms. These 
reforms move from merely sanctioning inappropriate 
antibiotic use to identifying the sociostructural factors 
driving antibiotic use and devising targeted incentives 
for locally tailored shifts to more appropriate antibiotic 
use.121–123 However, it remains unclear whether relying 
on local or even regional solutions will be able to solve 
the global challenge posed by AMR. Calls for behavioural 
change, industry reform and individualised policymaking 
have often been ineffective.34 77
Inequality
One of the most significant challenges facing interna-
tional antibiotic policy and global health frameworks 
more widely are significant levels of inequality between 
and within HICs and LMICs. These inequalities reflect 
historically uneven social and political opportunity as 
well as distribution of economic resources and disease 
burdens. Inequality has large implications for ways prior-
ities are made and implemented in relation to antibi-
otics. Recognition of these inequalities challenges forms 
of policymaking that focus on metrics of drug reduction 
alone (see Metrics and Implementation above) or prior-
itise protection of HIC hospital antibiotics over LMIC 
needs for access to antibiotics and protein production.
The unevenness of social and political opportunities 
affects who can make or demand policies. At the interna-
tional level, the historical dominance of HICs on relevant 
health bodies and many funders’ and high- level meetings’ 
location in HICs has led to a relative absence of the voices 
of some of the most affected LMIC stakeholders.124 There 
is a historically evidenced danger that this dominance of 
HIC voices can drown out LMIC concerns and lead to 
narrow policies centring on HIC concerns.125 126 Despite 
best intentions, motivations for international antibiotic 
policy initiatives must thus be considered uneven when 
framed with a health security lens—who is the ‘we’ in the 
need to act, and who is the ‘us’ being protected1?
Answering these questions is important. In the case of 
drug development, historical priority setting has been 
HIC- centric due to the greater profitability of high- 
income markets (with a particular emphasis on the most 
lucrative US market) and differing regional risk priori-
ties.111 127 In the case of surveillance, antibiotic resistance 
and usage indicators emerge unevenly from particular 
locations, prioritise particular security concerns and 
carry particular interpretations. When shuttling between 
different contexts in which resistance and use might have 
a different significance, these abstracted numeric indica-
tors can foster a contextual disconnect among decision- 
makers.128 The described surveillance disconnect is 
exacerbated by the relative lack of data from LICs and 
rural settings (see Metrics above). The result is a vicious 
circle: lacking access to equipment, current standards and 
scholarly literature means that disease and AMR burdens 
cannot be measured and published,32 which means that 
there are no data with which to build local expert capacity 
or inform international policy, which compounds the 
obscuring of difference between contexts.
Over time, decontextualised international decision 
making can result in policies that prioritise HIC- centric 
stewardship interventions like targeted drug restrictions 
that may prove deleterious in LMICs where infection 
risks are markedly higher and different.111 129 Limited 
data indicate an inverse correlation between countries' 
gross national income and invasive infections caused by 
WHO top- ranked antibiotic- resistant bacteria.71 Where 
resources are stretched thinly across health systems and 
infrastructure, other priorities than stewardship may 
be more pressing for investment. For example, IPC in 
health facilities and availability of effective WASH systems 
are essential. However, in 2017, ca. 785 million people 
worldwide had no access to safe drinking water, two of 
every seven people had no access to sanitation, and 22% 
of LIC health facilities had no water service.130 131 Indeed, 
investment in IPC and WASH is likely to be most effective 
for reducing AMR in many settings as a base on which 
stewardship might then be built.10 20 132 Furthermore, in 
many settings the ability to provide equitable access to 
essential medicines of sufficient quality, including antibi-
otics, remains elusive.10 112
Similar constraints are true for animal health which 
is related to issues such as food safety, food security and 
animal welfare. Many national and international action 
plans invoke enhanced biosecurity facilities, vaccina-
tion or good husbandry practices as a means to avoid 
unnecessary non- human antibiotic use, but they rarely 
set these measures as (funded) priorities contrary to 
raising awareness, developing surveillance or promoting 
responsible and prudent use, or they risk assuming inap-
propriate livestock production and disease management 
approaches in settings where economic and microbiolog-
ical risks are manifestly different.133–135 While arguments 
for wider systems strengthening should not undermine 
statutory antibiotic reform, decontextualised policies 
focusing only on antibiotic stewardship and surveillance 
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risk distracting from the even more important structural 
absence of adequate and situationally appropriate sani-
tary, veterinary and healthcare systems in many parts of 
the world.
HALLMARKS OF GOOD ANTIBIOTIC POLICY
The four biosocial challenges of metrics, prioritisa-
tion, implementation and inequality require a holistic 
response from international antibiotic policy that is ambi-
tious enough to improve the status quo but concrete and 
evocative enough to be an effective guide. Because such 
policies are enacted within a complex ecosystem, a broad 
perspective needs to inform their design and deployment 
to maximise effectiveness and minimise unintended 
consequences. It is this broad heuristic perspective, 
incorporating One Health, spatial, temporal and ethical 
dimensions that underlies the three interlinked SET hall-
marks proposed here (figure 1).
1. Structural: International antibiotic policies should 
recognise and respond to the multiple aspects of glob-
al antibiotic infrastructures.1 Since the 1930s, antibiot-
ics have replaced older, more expensive forms of infec-
tion control in humans, animals and plants and ena-
bled new medical interventions like organ transplants 
and prosthetic joint implants. Global health and food 
production systems rely on the comparatively cheap 
‘work’ performed by antibiotics. Reforming antibiotic 
use cannot be separated from broader reforms of the 
infrastructures that have evolved around them.
Historically, there has been a tendency to make AMR 
manageable by compartmentalising problems and 
blaming individuals for drug overuse instead of the 
underlying social, political and economic factors driv-
ing antibiotic demand and dependencies (see Metrics 
and Prioritisation).34 77 136 137 In HICs, a long- standing 
focus on technical quick fixes and individual behav-
ioural change meant that farmers and patients were 
routinely blamed for overuse without targeting wider 
infrastructural factors or the companies and experts 
supplying antibiotics.106 Bureaucratic divisions also 
meant that the same antibiotics could be subject to 
different regulations on farms and in clinics (see Im-
plementation). The fact that most reforms stopped 
at national borders further fragmented international 
regulation.76 88 136 Since the adoption of One Health 
terminology by WHO and EU antibiotic regulators 
around 2010,138 nearly all international AMR initia-
tives have attempted to overcome described problems 
by integrating polices for drug regulation in human 
medicine, animal production and the environment. 
However, beyond surveillance, One Health was ini-
tially often narrowly applied to mean ‘animals’ rath-
er than the wider environment—perhaps reflecting 
the absence of the UN Environmental Programme 
from the original Tripartite coalition of FAO, OIE and 
WHO. Recent European, Indian and private initia-
tives now explicitly target wastewaters and industrial 
wastes15 134 139 140 but implementing new standards re-
mains challenging. Meanwhile, our scientific under-
standing of the relative effect of antibiotics, metals and 
biocides on environmental AMR burdens and of the 
efficacy of proposed interventions remains fragmen-
tary.74 141 142
Successful antibiotic stewardship cannot be narrow 
and divorced from the social and environmental con-
texts in which use is taking place. More effective inter-
national policy requires the abandonment of regula-
tory silos, as well as the adoption of context- sensitive 
Figure 1 Interlinked hallmarks of successful antibiotic policy- making.
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models. It requires a broad structural approach to 
reforming not only the international antibiotic supply 
chain (drug producers) but also wider contributing 
global and regional consumption patterns (eg, rising 
global demand for protein) as well as associated socio- 
structural factors (eg, fractured health and WASH in-
frastructures, time constraints on diagnosis, profit in-
centives to prescribe or sell drugs) and environmental 
factors (eg, infection burdens, drug residues in water 
systems).
As evidenced by recent successes in HIC animal pro-
duction and health systems, jointly focusing on pre-
venting disease with vaccines and improved welfare, 
updating the design of surveillance, hospital, animal 
housing systems and modifying antibiotic- seeking be-
haviour by patients and animal and plant producers 
can reduce antibiotic dependencies.143–145 However, 
high- income infrastructural starting points cannot be 
taken for granted elsewhere in the globe (see the In-
equality section). To be effective internationally, the 
nature of ‘intervention’ must be less ‘AMR- specific’ 
and instead build up ‘AMR- sensitive’ changes20 which 
support wider UN SDGs including improved WASH, 
nutrition and access to affordable medical and vet-
erinary healthcare.10 20 While we do not discount the 
importance of traditional regulatory tools like actively 
enforced bans of over- the- counter sales, understand-
ing the work that antibiotics perform in non- HIC set-
tings may also lead to an interlayering of old and new 
policy tools such as subsidised assurance and disease 
insurance schemes for farmers phasing out antibiotics, 
access to high- income markets for animal and plant 
products produced without antibiotics, public anti-
biotic production or certified antibiotic distribution 
schemes.20 127 146 147
2. Equitable: To be impactful globally, international 
antibiotic policies must recognise and respond to the 
unevenness in contributions towards and ability to 
tackle AMR while aiming for an equitable future for 
antibiotics regardless of where they are deployed. His-
torically, inequality and the difficulty of uniform poli-
cy implementation across HICs and LMICs have been 
major obstacles for international antibiotic reform 
(see the Inequality and Metrics section).
Because antibiotic effectiveness is a time- limited glob-
al common pool resource and even robust national 
responses offer little protection from the global cir-
culation of AMR genes and organisms, the sustained 
pooling of international resources is an essential pre-
requisite to overcome identified challenges. Similar to 
climate change, some countries have a greater differ-
entiated responsibility to contribute resources to this 
common pool than others.110 For decades, popula-
tions in HICs have had greater access to the antimicro-
bial commons than their counterparts in LMICs. High 
volumes of HIC usage facilitated the historical selec-
tion for and global circulation of resistant genes and 
organisms while HIC companies disproportionately 
profited from early antibiotic sales. HICs’ historical 
contribution to current AMR levels and role in spread-
ing antibiotic dependent infrastructures to other parts 
of the world88 148 entail a moral obligation to bear a 
higher burden when it comes to mitigating resulting 
problems.110 Similarly, recent and projected high lev-
els of antibiotic use and production in MICs create a 
comparable obligation to contribute resources to mit-
igate problems in poorer areas of the world and for 
future generations.48 119 149 150
Whether action is justified on the basis of historical 
usage, collective responsibility, obligations towards 
future generations, or enlightened self- interest, any 
international policy framework will have to include 
long- term financial and political HIC and MIC com-
mitments to support antibiotic sensitive interventions 
in resource- poor communities. In LICs, antibiotic sen-
sitive international support could centre on building 
human and infrastructural capacity by educating and 
employing more medical and veterinary profession-
als,20 enhancing laboratory provision and expanding 
access to effective, affordable, and safe vaccines, an-
tibiotics, and WASH and health systems. From a One 
Health perspective, international policies should also 
promote economically and environmentally sustaina-
ble forms of animal and plant production as well as 
improve the management of waste containing antibi-
otics.
Well- designed structural and equitable international 
antibiotic policies can generate a global win- win.110 
Building LMIC capacity for disease control and pre-
vention and providing equitable access to effective 
treatments via market reforms, subsidies or public re-
search and development127 151 152 will lower both local 
disease burdens and rising international AMR- related 
healthcare costs.10 20 111 127 In the case of animal and 
plant production, equitable policies will recognise that 
to ensure regional food security, targets for a sustain-
able antibiotic- controlled production system can only 
come after an infrastructural groundwork is in place 
to reduce reliance on these substances.119 123
Because of its structural dimensions, the lack of an easy 
target and a dysfunctional commercial research and 
development pipeline for new antibiotics,127 147 AMR 
has so far failed to attract the same degree of resourc-
es that organisations like the Global Vaccine Alliance 
(GAVI) (est. 2000) or the Global Fund (2002) have 
mobilised for individual diseases like HIV/AIDS, tu-
berculosis, malaria or polio. Achieving truly structural 
and equitable global AMR solutions will depend on the 
more effective generation and pooling of investment 
in safe antibiotic access, coordination of country- level 
policy responses and provision of effective WASH, 
IPC and educational resources.127 This role could be 
fulfilled by the existing Tripartite and a One Health 
Global Leadership Group on AMR.153 Another option 
suggested by some authors is creating a new dedicat-
ed international AMR body or pooled fund similar to 
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GAVI.8 Ultimately, the structural challenges posed by 
AMR exceed the capabilities of any one nation. Over-
coming the significant levels of inequality that have 
hampered previous responses will depend on inten-
sifying international collaboration, equitably pooling 
resources and knowledge, and openly addressing the 
global disparities driving infectious disease burdens 
and the resulting need for antibiotics.
3. Tracked: Progress towards structural and equitable 
antibiotic policies has to be tracked to ensure ongoing 
effectiveness of interventions, promote integration of 
international efforts and motivate sustained commit-
ment of donors and funding recipients. While a reg-
ular independent international stocktake could help 
ensure that policy interventions remain coordinated, 
equitable and up to date,12 the metrics informing glob-
al decision making need to be reviewed and carefully 
chosen.128 To avoid reifying existing inequalities and 
HIC biosecurity concerns (see the Metrics section), 
tracked policies should be based on and promote sys-
tems of contextual data gathering that are: multifacto-
rial in their combination of existing and new metrics; 
integrated in their pooling of knowledge from differ-
ent One Health and regional contexts; and empower-
ing by conferring agency to local communities.
Multifactorial
Achieving effective tracked interventions requires a 
unifying global set of multifactorial metrics. To enable 
the rigorous evaluation of policies, multifactorial 
metrics need to simultaneously take into account antibi-
otic access, AMR and stewardship, but avoid rewarding 
short- termist gaming such as relabelling disease defi-
nitions, disincentivising healthcare- seeking behaviour 
and decontextualising surveillance (see the Inequality 
section).128 154 Standardised terminology and transparent 
AMR and drug usage surveillance are essential prereq-
uisites for the design of meaningful international inter-
ventions. However, focusing too narrowly on reducing 
drug usage and misuse will not curb microbial threats 
(see Implementation section). Vice versa, focusing only 
on providing drugs without supporting additional means 
to reduce disease burdens will achieve little in the long 
term. Since 2018, several ways have been proposed to 
integrate AMR into the UN SDG framework. The most 
recent proposal is to ‘reduce the percentage of blood-
stream infections due to selected antimicrobial resistant 
organisms’ and has been recommended to go forward 
to the UN Statistical Commission for inclusion in SDG 3 
(Good Health and Well- being).73 This is one promising 
way to address stewardship without detracting from the 
goals of antibiotic access and disease prevention (see the 
Metrics section). There is, however, an additional need 
for new multifactorial metrics that also encompass AMR’s 
environmental and animal health dimensions as well as 
local access to drugs, WASH, vaccines and coselection for 
resistance by other antimicrobial substances. The new 
monitoring and evaluation framework proposed by FAO, 
OIE and WHO in 2019 is an important step in this direc-
tion.155
Integrated
In addition to drawing on multifactorial metrics, policy 
tracking should aim to integrate metrics across domains: 
taking into account the legacies of pre- existing inter-
ventions, improving knowledge integration across One 
Health sectors and incorporating knowledge generated 
in other geographical and social contexts. Enhancing 
the integration of international knowledge gathering will 
strengthen regionally nuanced decision making. Since 
the 1940s, successive generations of regulators have 
tried to manage the antibiotic commons by focusing on 
one form of intervention like ‘rational’ antibiotic use, 
reducing antibiotic use via statutory bans or non- statutory 
incentives and replacing antibiotics (eg, using metals in 
animal feeds). However, lack of cross- sectoral and inter-
national integration meant that benefits were often 
short- lived and had little effect on global drug usage or 
AMR.34 76 137 156 157 Regulatory silos at the national and 
international level have also repeatedly impeded the 
transmission of knowledge generated in one sector to 
other sectors—something that is exacerbated by the fact 
that animal health, medical and environmental regula-
tors rarely interact on equal terms.158–160 In the case of 
AMR, the result was a lack of long- term strategic plan-
ning, a fragmentation of international policies and basic 
metrics (see the Metrics section)—and a tendency to 
reinvent the wheel—for example, the almost decennial 
recurrence of official warnings about post- antibiotic 
futures and ‘rational’ antibiotic use campaigns.77 161 
Developing equitable structural policy frameworks thus 
not only depends on evaluating progress with multifac-
torial metrics but also on actively integrating knowledge 
throughout the One Health domains, leveraging existing 
national and regional policy frameworks and retaining 
institutional knowledge.
Empowering
Developing multifactorial and integrated metrics will 
achieve little if global AMR and usage data continues 
to be generated and made available unevenly. Equitably 
boosting laboratory and data analysis capacity is a prereq-
uisite for strengthening the ability of those on the front 
lines of human, animal and plant health to devise their 
own solutions and generate accurate data for the global 
community. For example, in 2010, the Danish Yellow Card 
Initiative required farmers and veterinarians to track and 
record on farm antibiotic use. The initiative comple-
mented low- granularity sales data and helped respective 
communities better understand what they were doing 
and grow support for stewardship efforts.54 In LMICs, 
enhancing national and local capacity to generate data 
can have similar effects. Being able to produce and wield 
robust surveillance data can increase the political weight 
of LMIC concerns at the international level. OIE, WHO 
and the UK Fleming Fund are already strengthening 
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LIC usage and AMR surveillance capacity. However, 
organisations still lack sufficient resources to sustainably 
support laboratories and countries to enable them to 
publish accurate country- level data.29 New multifacto-
rial and integrated metrics are also needed to produce 
data that is meaningful in settings without formal health 
and veterinary care systems. In the long term, reducing 
reliance on decontextualised data gathering like trav-
eller surveillance and restructuring reporting formats to 
better reflect varying circumstances (see the Inequality 
section) will significantly enhance the evidence base for 
truly structural and equitable international antibiotic 
policy- making.
CONCLUSION
The past eight decades have seen antibiotic policy- makers 
struggle to overcome problematic metrics, narrow prior-
itisations, implementation deficits and global inequali-
ties. The need for integrated architectures that act across 
existing silos to push evidence into action on AMR is 
being met through United Nations mandated mecha-
nisms.10 To move beyond previous impasses, interna-
tional policy will have to take seriously the infrastructural 
dimensions of antibiotic use, provide equitable solutions 
for communities across the globe and develop new forms 
of tracking progress that are multifactorial, integrated 
and empowering for the communities employing them.
Policies that take into account antibiotics’ SET have 
the greatest potential to sustainably adapt the way the 
global antibiotic commons are managed and accessed. As 
highlighted in our ideal- type example of multifactorial 
metrics and equitable capacity building in global food 
production (figure 2), SET policies have the potential to 
foster win- win situations for HIC and LMIC participants 
alike.
If the ultimate goal of antibiotic policy is to reduce 
mortality and morbidity resulting from treatable infec-
tions, then we need to adapt our food and health systems 
to provide optimal access to effective antibiotic interven-
tions when they are needed—and simultaneously reduce 
the need for these interventions. This dual approach 
requires polices that not only focus on ‘quick fixes’106 
for existing systems and behavioural modifications at the 
level of the individual. Instead, policies should consis-
tently seek to adapt the wider physical and cultural infra-
structures antibiotics are embedded in.
AMR is not a problem to be solved but a phenomenon 
to be continuously managed. Individual policies may not 
address all identified problem areas or integrate each of 
our three intervention hallmarks. However, we believe 
that our multidisciplinary SET of hallmarks can serve as 
a compass to critically evaluate and improve antibiotic 
policy in the present and for decades to come.
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